Table 4. Impact of BRCA1/2 P/LP variants and other variables on the DFS and OS of breast cancer patients (Stage 0~III).

Variables	DFS			OS
	#Cases (events)	HR (95% CI) a	P	#Cases (deaths)	HR (95% CI) a	P
Germline and somatic combined variants
Non-carrier	380 (35)	1		380 (20)	1
BRCA1/2	46 (3)	0.69 (0.21–2.25)	0.54	46 (0)	0	0.30
BRCA1	19 (3)	1.78 (0.55–5.81)	0.34	19 (0)	0	0.51
BRCA2	27 (0)	0	0.98	27 (0)	0	0.42
Germline variants
Non-carrier	380 (35)	1		380 (20)	1
BRCA1/2	36 (3)	0.94 (0.29–3.06)	0.92	36 (0)	0	0.37
BRCA1	16 (3)	2.22 (0.68–7.26)	0.19	16 (0)	0	0.55
BRCA2	20 (0)	0	0.97	20 (0)	0	0.50
Somatic variants
Non-carrier	380 (35)	1		380 (20)	1
BRCA1/2	9 (0)	0	0.49	9 (0)	0	0.60
Age at diagnosis	426 (38)	1.01 (0.98–1.05)	0.38	426 (20)	1.03 (0.99–1.08)	0.11
Menopause at diagnosis
Postmenopause	188 (24)	2.22 (1.15–4.29)	0.02	188 (15)	3.81 (1.38–10.49)	0.01
Premenopause	235 (14)	1		235 (5)	1
Molecular subtype
Luminal A	49 (2)	0.28 (0.06–1.3)	0.10	49 (1)	0.26 (0.03–2.34)	0.23
Luminal B	241 (16)	0.48 (0.21–1.12)	0.09	241 (8)	0.46 (0.14–1.53)	0.20
HER2+	59 (8)	1.00 (0.37–2.66)	1.00	59 (4)	0.95 (0.24–3.83)	0.95
TN	60 (8)	1		60 (4)	1
ER-PR+	17 (4)	1.9 (0.57–6.31)	0.30	17 (3)	2.62 (0.58–11.75)	0.21
Histological grade
I/II	133 (5)	1		133 (3)	1
III	264 (33)	3.54 (1.38–9.07)	0.008	264 (17)	2.92 (0.86–9.99)	0.09
Clinical stage
0/I	67 (2)	0.15 (0.04–0.67)	0.01	67 (0)	0	0.96
II	256 (18)	0.39 (0.2–0.74)	0.004	256 (8)	0.26 (0.11–0.64)	0.003
III	103 (18)	1		103 (12)	1
Standard therapy
No	16 (3)	1		16 (2)	1
Yes	410 (35)	0.32 (0.1–1.03)	0.06	410 (18)	0.22 (0.05–0.97)	0.05

^a Univariate Cox proportional hazards regression models